NCT02741570: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- State
- Completed
- Phase
- Phase 3
- People
- 947 taking part
- Started
- 5 Oct 2016
- Primary completion
- 10 May 2021
- Arms
- Nivolumab and Ipilimumab
- Results
- Posted on the registry
- 18 Apr 2016: Trial registered
- 5 Oct 2016: Trial started
- 3 May 2022: Trial results posted
- 22 Sep 2022: Trial completed